AZD5363 inhibited AKT and mTOR activity, and increased LC3-II flux in PC3 cells. Baf A1, CQ, 3MA, siATG3 or siATG7 increased AZD5363-induced apoptosis in PC3 cells. AZD5363 + CQ co-treatment reduced PC3 and DU145 xenograft tumour growth. Here, MAP1LC3A is linked to neoplasm.